NCT06145139Enrolling by invitation
KIDNEY-PAGER: Analysis of Circulating Tumor DNA as a Biomarker in Renal Cancer - an Observational Trial
KIDNEY-PAGER: Analysis of Circulating Tumor DNA as a Biomarker in Renal Cancer
Source: ClinicalTrials.gov · Last updated 22 Nov 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The overall aim of this observational study is to confirm that circulating tumor DNA (ctDNA) detected in plasma and or urine after intended curative treatment for renal cell carcinoma (RCC) can be applied in clinical practice as a marker of subclinical residual disease and risk of recurrence.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 15 Nov 2023
- Start date
- 1 Jun 2023
- Primary completion date
- 1 Jun 2028
- Lead sponsor
- University of Aarhus
- Diseases
- Kidney cancer
- NCT number
- NCT06145139
What you commit to
- Study type: Observational
- Planned participants: 500
- From 1 Jun 2023 to the primary completion date, 1 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with local disease who are not being offered a nephrectomy.
Other
- Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and/or otherwise considered by the Investigator to be unlikely to complete the study
Who the study is looking for
- Patients diagnosed with a locoregional cancer in the kidney, and with a tumour available for surgical excision, and sufficient performance status for surgery.
- Patients with M1 disease, but no evidence of disease after surgery and local treatment of the metastases.
- Core needle biopsy-proven renal cell carcinoma - all histologic subtypes acceptable, clinical tumour stage I-IV
- Patients 18 years or older
- Patients able to understand and sign written informed consent
- Scheduled for curative intent resectional surgery (partial or radical nephrectomy)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Urology Department Aarhus University Hospital Coordinator of this site? Confirm its status | Aarhus N | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.